Studying cd38 and cd56 in chronic myeloid leukemia

This study looks at levels of a protein called CD47 in people with chronic myeloid leukemia (CML). CD47 is sometimes called the 'do not eat me' signal because it may help cancer cells hide from the immune system. Understanding this could lead to better treatments.

This study uses a very sensitive blood test (digital PCR) to look for specific genetic mutations (changes) in the BCR::ABL1 gene in people with CML. The goal is to understand why some treatments stop working, which can help doctors choose the next best medication for you.

This trial is a real-life study that collects information from people living with chronic myeloid leukemia (CML). It may help doctors understand how CML treatments are used in practice and how well they work over time.

This trial looks at a marker called CD56 in people who have been newly diagnosed with a blood cancer (a hematologic malignancy). The results may help doctors better understand the disease and guide future treatment choices.

This research study examines blood cells from patients with chronic myelomonocytic leukemia (CMML), a rare blood cancer, to better understand how the disease develops and progresses. By studying your blood cells, researchers hope to learn more about what causes CMML and how to treat it better.

This trial looks at two markers, CLL1 and CD45RA, found on some leukemia cells. It aims to help doctors better understand and treat acute myeloid leukemia (AML) by measuring these markers at diagnosis.